<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025439</url>
  </required_header>
  <id_info>
    <org_study_id>1R21HD075192</org_study_id>
    <nct_id>NCT02025439</nct_id>
  </id_info>
  <brief_title>Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness</brief_title>
  <official_title>Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Hines Jr. VA Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edward Hines Jr. VA Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of repetitive transcranial&#xD;
      magnetic stimulation (rTMS) combined with Amantadine relative to rTMS Alone and Amantadine&#xD;
      Alone for persons in chronic states of seriously impaired consciousness. The hypothesis is&#xD;
      that provision of rTMS+Amantadine will provide a safe yet synergistic effect that induces or&#xD;
      accelerates functional recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The R21 research objective is to examine the safety and efficacy of repetitive transcranial&#xD;
      magnetic stimulation (rTMS) combined with Amantadine (TMS + Amantadine) relative to rTMS&#xD;
      Alone and Amantadine Alone for persons in chronic states of seriously impaired consciousness.&#xD;
      The hypothesis is that provision of rTMS+Amantadine will provide a safe yet synergistic&#xD;
      effect that induces or accelerates functional recovery. This hypothesis is based on (a)&#xD;
      preliminary data indicating partially improved neurobehavioral functioning mechanistically&#xD;
      related to rTMS-induced neural activity and connectivity as well as improved integrity of&#xD;
      white fiber tracts, (b) relationship between dopamine (DA) and common traumatic brain injury&#xD;
      (TBI) impairments, (c) role of DA in mediating consciousness, (d) the commonality between and&#xD;
      DA and rTMS-targeted pathways, (e) clinical efficacy and safety of Amantadine, (f) mechanisms&#xD;
      of action of Amantadine, and (g) the association between rTMS and Amantadine with&#xD;
      up-regulating brain derived neurotrophic factor. The rationale is that pairing rTMS with&#xD;
      Amantadine will have a complementary and synergistic effect on factors promoting conscious&#xD;
      behavior. The specific aims are to: (1) Demonstrate that rTMS+Amantadine is safely tolerated,&#xD;
      (2) Determine neurobehavioral effect of rTMS+Amantadine, and (3) Characterize pre-and&#xD;
      post-treatment neural changes in neural activation. Aim 1 is based on our preliminary safety&#xD;
      data and safety data regarding Amantadine. To address Aims 2 &amp; 3 we use a repeated measures&#xD;
      baseline control design with randomized treatment orders yielding three treatment groups;&#xD;
      rTMS + Amantadine, rTMS Alone and Amantadine Alone. Analyses for Aims 2 and 3 involve&#xD;
      comparing these treatment groups according to neurobehavioral growth trajectories, mean&#xD;
      amount of neural activation and connectivity within and between brain regions, and indices of&#xD;
      fiber tract directionality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of Adverse Event</measure>
    <time_frame>30 days after treatment &quot;alone&quot; and an additional 30 days after treatment &quot;combined&quot; (i.e., 60 days)</time_frame>
    <description>If an adverse event occurred, the intensity was also indicated. The intensity of an adverse event was determined using a scale from 1-5 with 5 being the worst. The purpose of the study is to examine safety of rTMS combined with AMA relative to rTMS Alone and AMA alone. Results are not reported &quot;per arm&quot; rather, the arms are combined so as to compare the outcome when the interventions are provided separately (i.e., rTMS alone and amantadine alone) vs interventions are combined (rTMS +Amantadine alone).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>rTMS Alone followed by rTMS+AMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMA Alone followed by rTMS+AMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <arm_group_label>AMA Alone followed by rTMS+AMA</arm_group_label>
    <arm_group_label>rTMS Alone followed by rTMS+AMA</arm_group_label>
    <other_name>Repetitive Transcranial Magnetic Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <arm_group_label>AMA Alone followed by rTMS+AMA</arm_group_label>
    <arm_group_label>rTMS Alone followed by rTMS+AMA</arm_group_label>
    <other_name>Symadine</other_name>
    <other_name>Symmetrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-64 years of age&#xD;
&#xD;
          -  Suffered a severe brain injury of traumatic origin at least 1-year prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Remain in a state of disordered consciousness&#xD;
&#xD;
          -  Brain injuries will include injury with resulting coup-contre-coup injuries, excluding&#xD;
             persons with trauma due to blunt injuries and/or non-traumatic encephalopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have 1 or more Amantadine contraindications: On monoamino oxidase inhibitor-B,&#xD;
             hypersensitivity/idiosyncrasy to sympathomimetic amines, uncontrolled hypertension,&#xD;
             glaucoma or Congestive Heart Failure&#xD;
&#xD;
          -  Have contraindications to Amantadine Dose of 200 mg Daily as determined by estimated&#xD;
             Glomerular Filtration Rate (eGFR) â‰¤ 60 (ml/min)&#xD;
&#xD;
          -  Abnormal results of Liver Function Test at screening&#xD;
&#xD;
          -  Receiving anti-epileptic medications to control active seizures or have had a&#xD;
             documented seizure within three months of study enrollment&#xD;
&#xD;
          -  Incurred large cortically based ischemic infarction/encephalomalacia subsequent to TBI&#xD;
&#xD;
          -  Have documented history of previous TBI, psychiatric illness (DSM criteria) and/or&#xD;
             organic brain syndrome such as Alzheimer's&#xD;
&#xD;
          -  Are using medications which may interfere with Amantadine and cannot be safely&#xD;
             titrated or discontinued&#xD;
&#xD;
          -  Are pregnant&#xD;
&#xD;
          -  Have implanted cardiac pacemaker or defibrillator, cochlear implant, nerve stimulator,&#xD;
             intracranial metal clips&#xD;
&#xD;
          -  Have MRI and/or TMS contraindications such as: History of claustrophobia, metal in&#xD;
             eyes/face, shrapnel/bullet remnants in brain&#xD;
&#xD;
          -  Are fully conscious as indicated by a score of 6 on the Motor Function scale and/or a&#xD;
             score of 2 on the Communication scale of the CRS-R,&#xD;
&#xD;
          -  Are within first year of injury&#xD;
&#xD;
          -  Are &lt;18 years of age and &gt; 65 years of age&#xD;
&#xD;
          -  Have an injury or condition due to blunt trauma only or non-traumatic encephalopathy&#xD;
&#xD;
          -  Have programmable CSF shunt or are ventilator dependent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa BenderPape, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward Hines Jr. VA Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines, Jr. VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pape TL, Rosenow J, Lewis G. Transcranial magnetic stimulation: a possible treatment for TBI. J Head Trauma Rehabil. 2006 Sep-Oct;21(5):437-51. Review.</citation>
    <PMID>16983227</PMID>
  </reference>
  <reference>
    <citation>Louise-Bender Pape T, Rosenow J, Lewis G, Ahmed G, Walker M, Guernon A, Roth H, Patil V. Repetitive transcranial magnetic stimulation-associated neurobehavioral gains during coma recovery. Brain Stimul. 2009 Jan;2(1):22-35. doi: 10.1016/j.brs.2008.09.004. Epub 2008 Oct 23.</citation>
    <PMID>20633400</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <results_first_submitted>July 29, 2019</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Edward Hines Jr. VA Hospital</investigator_affiliation>
    <investigator_full_name>Theresa Pape</investigator_full_name>
    <investigator_title>Clinical Neuroscientist</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>Amantadine</keyword>
  <keyword>Vegetative State</keyword>
  <keyword>Minimally Conscious State</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>nothing to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rTMS Alone Followed by rTMS+AMA</title>
          <description>Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.upon completion of assigned treatment order, the subject will then receive 30 sessions of combination therapy of rTMS + Amantadine&#xD;
rTMS</description>
        </group>
        <group group_id="P2">
          <title>AMA Alone Followed by rTMS+AMA</title>
          <description>Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. upon completion of assigned treatment order, the subject will then receive 30 sessions of combination therapy of rTMS + Amantadine&#xD;
Amantadine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rTMS First</title>
          <description>Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.&#xD;
rTMS</description>
        </group>
        <group group_id="B2">
          <title>Amantadine First</title>
          <description>Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days.&#xD;
Amantadine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21" upper_limit="27"/>
                    <measurement group_id="B2" value="33" lower_limit="28" upper_limit="37"/>
                    <measurement group_id="B3" value="28" lower_limit="21" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intensity of Adverse Event</title>
        <description>If an adverse event occurred, the intensity was also indicated. The intensity of an adverse event was determined using a scale from 1-5 with 5 being the worst. The purpose of the study is to examine safety of rTMS combined with AMA relative to rTMS Alone and AMA alone. Results are not reported &quot;per arm&quot; rather, the arms are combined so as to compare the outcome when the interventions are provided separately (i.e., rTMS alone and amantadine alone) vs interventions are combined (rTMS +Amantadine alone).</description>
        <time_frame>30 days after treatment &quot;alone&quot; and an additional 30 days after treatment &quot;combined&quot; (i.e., 60 days)</time_frame>
        <population>Results are reported both &quot;per arm&quot; at the end of 30 days when a single treatment (either rTMS or AMA) was ended, and additional results are reported with both arms combined to report the outcome after 60 days</population>
        <group_list>
          <group group_id="O1">
            <title>rTMS Alone</title>
            <description>Subjects assigned to start with rTMS Alone</description>
          </group>
          <group group_id="O2">
            <title>rTMS+AMA</title>
            <description>All subjects that received rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.</description>
          </group>
          <group group_id="O3">
            <title>AMA Alone</title>
            <description>Subjects assigned to start with amantadine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Adverse Event</title>
          <description>If an adverse event occurred, the intensity was also indicated. The intensity of an adverse event was determined using a scale from 1-5 with 5 being the worst. The purpose of the study is to examine safety of rTMS combined with AMA relative to rTMS Alone and AMA alone. Results are not reported &quot;per arm&quot; rather, the arms are combined so as to compare the outcome when the interventions are provided separately (i.e., rTMS alone and amantadine alone) vs interventions are combined (rTMS +Amantadine alone).</description>
          <population>Results are reported both &quot;per arm&quot; at the end of 30 days when a single treatment (either rTMS or AMA) was ended, and additional results are reported with both arms combined to report the outcome after 60 days</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.52"/>
                    <measurement group_id="O2" value="0.98" spread="0.38"/>
                    <measurement group_id="O3" value="0.33" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months and 6 months</time_frame>
      <desc>A Clinical Data Monitoring Log was used to record. Most were collected daily. CNS changes were collected once during MRI scan. clinical indices include fatigue, fever, hypertension, hypotension, infection at IV site, weight loss/gain, seizures, skin breakdown at IV site, skin breakdown on scalp, general skin breakdown, sweating and neurochecks hourly between rTMS sessions on the same day.</desc>
      <group_list>
        <group group_id="E1">
          <title>rTMS Alone</title>
          <description>Subjects assigned to rTMS Alone 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.</description>
        </group>
        <group group_id="E2">
          <title>rTMS+AMA</title>
          <description>Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days.Then, A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.</description>
        </group>
        <group group_id="E3">
          <title>AMA Alone</title>
          <description>Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="19" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection at IV site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neurocheck</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin breakdown at venous site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>General Skin Integrity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin breakdown at scalp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa Bender-Pape</name_or_title>
      <organization>Edward Hines VA Hospital</organization>
      <phone>708-202-4953</phone>
      <email>Theresa.BenderPape@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

